Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05796674 · ClinicalTrials.gov registry record
Clareon IOL Retrospective Data Collection
A clinical trial, sponsored by Alcon Research.
- Completed
- Registry status
- 1,090
- Enrollment target
NCT05796674: Completed study, sponsored by Alcon Research.
NCT05796674 is a clinical trial that has completed, run by Alcon Research. The registered enrollment target is 1,090 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05796674 has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- 1,090 participants
- Enrollment target
Study Summary
The purpose of this study is to provide real world evidence (RWE) on the performance of the Clareon ultraviolet absorbing (UVA) intraocular lenses (IOLs) to support the overall body of evidence on the Clareon IOL family.
Primary Outcome
The database will be reviewed for assessments of monocular (by-eye) best corrected distance visual acuity at the first postoperative visit. The first postoperative visit will be defined as the visit which occurred approximately 28 days or later from the operative visit during which time the IOL remained implanted in the eye and an eye exam was performed.
Interventions
- PROCEDURE Cataract surgery
- DEVICE Clareon UVA IOL
- DEVICE WaveTec Optiwave Refractive Analysis (ORA) System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,090 participants |
| Start Date | 2023-08-18 |
| Est. Completion | 2023-09-12 |
What the finished NCT05796674 record still lists
NCT05796674 is an observational study that tracks outcomes without assigning an intervention. Its 1,090 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which Cataract surgery is the first listed.
NCT05796674 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05796674 about?
NCT05796674 is a clinical study titled "Clareon IOL Retrospective Data Collection". The purpose of this study is to provide real world evidence (RWE) on the performance of the Clareon ultraviolet absorbing (UVA) intraocular lenses (IOLs) to support the overall body of evidence on the Clareon IOL family.
What is the current status of trial NCT05796674?
This trial is currently completed. The enrollment target is 1,090 participants. The study started on 2023-08-18. Estimated completion is 2023-09-12.
What interventions are being tested in trial NCT05796674?
The interventions under investigation include: Cataract surgery (PROCEDURE), Clareon UVA IOL (DEVICE), WaveTec Optiwave Refractive Analysis (ORA) System (DEVICE).
Who is sponsoring clinical trial NCT05796674?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- NCT06671483 · 1,088 participants · Phase 3
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
- NCT03754114 · 1,094 participants · NA
Brain Oxygen Optimization in Severe TBI, Phase 3
- NCT06118983 · 1,094 participants · NA
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI